2024
RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI
Sundaresan V, Webb L, Rabil M, Golos A, Sutherland R, Sprenkle P, Kim I, Leapman M. RISKS OF GRADE RECLASSIFICATION AMONG PATIENTS WITH GLEASON GRADE GROUP 1 PROSTATE CANCER AND PI-RADS 5 FINDINGS ON PROSTATE MRI. Urologic Oncology Seminars And Original Investigations 2024, 42: s79. DOI: 10.1016/j.urolonc.2024.01.222.Peer-Reviewed Original ResearchGleason Grade Group 1PI-RADS 5 lesionsPI-RADSProstate biopsyProstate cancerGleason upgradingRadical prostatectomyActive surveillanceProstate MRIMultivariate logistic regressionGrade Group 1 prostate cancerConversion to active treatmentOptimal management of patientsGrade group 1PI-RADS 5Gleason grade groupProstate Imaging ReportingDied of diseaseManagement of patientsLogistic regressionPrimary study outcomeAssociated with oddsMedian PSAMetastatic diseaseGrade disease
2023
Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer
Jalfon M, Sakhalkar O, Lokeshwar S, Marks V, Choksi A, Klaassen Z, Leapman M, Kim I. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports 2023, 24: 455-461. PMID: 37369828, DOI: 10.1007/s11934-023-01173-6.Peer-Reviewed Original ResearchConceptsOligometastatic prostate cancerCytoreductive radical prostatectomyMetastatic prostate cancerProstate cancerLocal therapyRadiation therapySystemic therapyClinical trialsDe novo metastatic prostate cancerProgression-free survivalWidespread metastatic diseaseStandard of careRecent FindingsTo dateClinician decision makingCytoreductive prostatectomySystemic chemotherapyMetastatic diseaseWidespread metastasesRetrospective studyRadical prostatectomyEarly treatmentLocal treatmentTreatment selectionTherapyPatients
2020
Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strata